What they were paid
Allogene Therapeutics Director Compensation Table · all 5 fiscal years held| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2025 | $60,000 | $123,066 | $0 | $0 | $183,066 |
| FY2024 | $54,890 | $0 | $298,650 | $0 | $353,540 |
| FY2023 | $52,500 | $0 | $423,933 | $0 | $476,433 |
| FY2022 | $52,500 | $0 | $430,762 | $0 | $483,262 |
| FY2021 | $18,750 | $0 | $844,582 | $0 | $863,332 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Allogene Therapeutics, Inc. DEF 14A filed April 30, 2026, accession 0001628280-26-028948, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Allogene Therapeutics, Inc. filed document, accession 0001628280-26-028948. Every figure is read from that document and cited to the page and table it appears in. Filed April 30, 2026.
Get the Allogene Therapeutics Board Governance Report
$183,066 Elizabeth Barrett, FY2025 total director compensation
$500
The free page is the headline figures. The board report is director pay, board composition and committee fees combined into the same kind of document.
Data as of April 30, 2026 · Source: Velarion Executive Compensation Database, deposited on Zenodo (doi:10.5281/zenodo.22283855).
How this board is paid
company policy · FY2025Allogene Therapeutics pays directors a $40,000 cash retainer and $300,000 in RSUs/Options.
Committees
FY2025 · as the proxy prints themAudit · Compensation
The rest of the Allogene Therapeutics board
FY2025 · as the company reported each| Director | Role | FY2025 total |
|---|---|---|
| Arie Belldegrun, M.D | Chair of the Board | $4,077,520 |
| David Bonderman | Independent Director | $0 |
| David Chang, M.D., Ph.D | Director | — |
| Deborah Messemer | Independent Director | $193,066 |
| Franz Humer, Ph.D | Independent Director | $274,879 |
| John DeYoung | Independent Director | $0 |
| Joshua Kazam | Director | $170,066 |
| Owen Witte, M.D | Independent Director | $193,066 |
| Stephen Mayo, Ph.D | Independent Director | $181,642 |
| Todd Sisitsky | Independent Director | $0 |
| Vicki Sato, Ph.D | Independent Director | $182,224 |
The full Allogene Therapeutics compensation record
free company briefThis page is one director within Allogene Therapeutics's record. The company brief lists every named executive and director, each linking to their own page.
Peer companies
named in the Allogene Therapeutics proxy · each links to its own free briefOrder ALLO
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.